Onconova sinks as Baxter backs away from oral rigosertib

Onconova Therapeutics sank 36.3% to close at $2.55 per share on 3 February after the company revealed deep in a disclosure of its Phase III plans for intravenous rigosertib in higher-risk myelodysplastic syndrome (MDS) that its partner Baxter Healthcare will not pursue further development of oral rigosertib in lower-risk MDS.